Fingolimod suppresses bone resorption in female patients with multiple sclerosis
Abstract Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patie...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 2016-09, Vol.298, p.24-31 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 31 |
|---|---|
| container_issue | |
| container_start_page | 24 |
| container_title | Journal of neuroimmunology |
| container_volume | 298 |
| creator | Miyazaki, Yusei Niino, Masaaki Kanazawa, Ippei Suzuki, Masako Mizuno, Masanori Hisahara, Shin Fukazawa, Toshiyuki Takahashi, Eri Amino, Itaru Ochi, Ryutaro Nakamura, Masakazu Akimoto, Sachiko Minami, Naoya Fujiki, Naoto Doi, Shizuki Shimohama, Shun Terayama, Yasuo Kikuchi, Seiji |
| description | Abstract Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N -telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients. |
| doi_str_mv | 10.1016/j.jneuroim.2016.06.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827915452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572816301394</els_id><sourcerecordid>1818338020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-7ca27b820a26924b4261052306efaf84fb91082c5cfc0542c9f08340e3d4f0f43</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhS1ERW8Lr1BlySa345_EzgaBKgpIlUBqWVuJMwYHxw52Aurb11e3ZcGm0khjj8-ckb8h5ILCngJtL6f9FHBL0c17Vu57KAHyBdlRJVmtBKMvya48NHUjmTolZzlPALThontFTplsoWOS7ci3axd-RO_mOFZ5W5aEOWOuhhiwKueYltXFULlQWZx7j9XSrw7Dmqu_bv1ZzZtf3VLK2XhMMbv8mpzY3md885jPyffrj3dXn-ubr5--XH24qY1o2rWWpmdyUAx61nZMDIK1FBrGoUXbWyXs0FFQzDTGGmgEM50FxQUgH4UFK_g5eXv0XVL8vWFe9eyyQe_7gHHLmiomO9qI4vm8lCrOFTAo0vYoNeUzOaHVS3Jzn-41BX0Aryf9BF4fwGsoAbI0XjzO2IYZx39tT6SL4P1RgAXKH4dJZ1NAGhxdQrPqMbrnZ7z7z8J4F5zp_S-8xzzFLYWCXFOdmQZ9e1j_Yfu05UB5J_gDLfas-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1818338020</pqid></control><display><type>article</type><title>Fingolimod suppresses bone resorption in female patients with multiple sclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Miyazaki, Yusei ; Niino, Masaaki ; Kanazawa, Ippei ; Suzuki, Masako ; Mizuno, Masanori ; Hisahara, Shin ; Fukazawa, Toshiyuki ; Takahashi, Eri ; Amino, Itaru ; Ochi, Ryutaro ; Nakamura, Masakazu ; Akimoto, Sachiko ; Minami, Naoya ; Fujiki, Naoto ; Doi, Shizuki ; Shimohama, Shun ; Terayama, Yasuo ; Kikuchi, Seiji</creator><creatorcontrib>Miyazaki, Yusei ; Niino, Masaaki ; Kanazawa, Ippei ; Suzuki, Masako ; Mizuno, Masanori ; Hisahara, Shin ; Fukazawa, Toshiyuki ; Takahashi, Eri ; Amino, Itaru ; Ochi, Ryutaro ; Nakamura, Masakazu ; Akimoto, Sachiko ; Minami, Naoya ; Fujiki, Naoto ; Doi, Shizuki ; Shimohama, Shun ; Terayama, Yasuo ; Kikuchi, Seiji</creatorcontrib><description>Abstract Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N -telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2016.06.007</identifier><identifier>PMID: 27609272</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Allergy and Immunology ; Bone resorption ; Bone Resorption - drug therapy ; Bone Resorption - etiology ; Collagen Type I - urine ; Disability Evaluation ; Female ; Fingolimod ; Fingolimod Hydrochloride - therapeutic use ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - complications ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - urine ; Neurology ; Osteoclasts ; Osteoporosis ; Peptide Fragments - metabolism ; Peptides - urine ; Procollagen - metabolism ; Sex Characteristics ; Sphingosine-1-phosphate ; Tartrate-Resistant Acid Phosphatase - metabolism</subject><ispartof>Journal of neuroimmunology, 2016-09, Vol.298, p.24-31</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-7ca27b820a26924b4261052306efaf84fb91082c5cfc0542c9f08340e3d4f0f43</citedby><cites>FETCH-LOGICAL-c456t-7ca27b820a26924b4261052306efaf84fb91082c5cfc0542c9f08340e3d4f0f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165572816301394$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27609272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyazaki, Yusei</creatorcontrib><creatorcontrib>Niino, Masaaki</creatorcontrib><creatorcontrib>Kanazawa, Ippei</creatorcontrib><creatorcontrib>Suzuki, Masako</creatorcontrib><creatorcontrib>Mizuno, Masanori</creatorcontrib><creatorcontrib>Hisahara, Shin</creatorcontrib><creatorcontrib>Fukazawa, Toshiyuki</creatorcontrib><creatorcontrib>Takahashi, Eri</creatorcontrib><creatorcontrib>Amino, Itaru</creatorcontrib><creatorcontrib>Ochi, Ryutaro</creatorcontrib><creatorcontrib>Nakamura, Masakazu</creatorcontrib><creatorcontrib>Akimoto, Sachiko</creatorcontrib><creatorcontrib>Minami, Naoya</creatorcontrib><creatorcontrib>Fujiki, Naoto</creatorcontrib><creatorcontrib>Doi, Shizuki</creatorcontrib><creatorcontrib>Shimohama, Shun</creatorcontrib><creatorcontrib>Terayama, Yasuo</creatorcontrib><creatorcontrib>Kikuchi, Seiji</creatorcontrib><title>Fingolimod suppresses bone resorption in female patients with multiple sclerosis</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Abstract Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N -telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.</description><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Bone resorption</subject><subject>Bone Resorption - drug therapy</subject><subject>Bone Resorption - etiology</subject><subject>Collagen Type I - urine</subject><subject>Disability Evaluation</subject><subject>Female</subject><subject>Fingolimod</subject><subject>Fingolimod Hydrochloride - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - complications</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - urine</subject><subject>Neurology</subject><subject>Osteoclasts</subject><subject>Osteoporosis</subject><subject>Peptide Fragments - metabolism</subject><subject>Peptides - urine</subject><subject>Procollagen - metabolism</subject><subject>Sex Characteristics</subject><subject>Sphingosine-1-phosphate</subject><subject>Tartrate-Resistant Acid Phosphatase - metabolism</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1TAQhS1ERW8Lr1BlySa345_EzgaBKgpIlUBqWVuJMwYHxw52Aurb11e3ZcGm0khjj8-ckb8h5ILCngJtL6f9FHBL0c17Vu57KAHyBdlRJVmtBKMvya48NHUjmTolZzlPALThontFTplsoWOS7ci3axd-RO_mOFZ5W5aEOWOuhhiwKueYltXFULlQWZx7j9XSrw7Dmqu_bv1ZzZtf3VLK2XhMMbv8mpzY3md885jPyffrj3dXn-ubr5--XH24qY1o2rWWpmdyUAx61nZMDIK1FBrGoUXbWyXs0FFQzDTGGmgEM50FxQUgH4UFK_g5eXv0XVL8vWFe9eyyQe_7gHHLmiomO9qI4vm8lCrOFTAo0vYoNeUzOaHVS3Jzn-41BX0Aryf9BF4fwGsoAbI0XjzO2IYZx39tT6SL4P1RgAXKH4dJZ1NAGhxdQrPqMbrnZ7z7z8J4F5zp_S-8xzzFLYWCXFOdmQZ9e1j_Yfu05UB5J_gDLfas-Q</recordid><startdate>20160915</startdate><enddate>20160915</enddate><creator>Miyazaki, Yusei</creator><creator>Niino, Masaaki</creator><creator>Kanazawa, Ippei</creator><creator>Suzuki, Masako</creator><creator>Mizuno, Masanori</creator><creator>Hisahara, Shin</creator><creator>Fukazawa, Toshiyuki</creator><creator>Takahashi, Eri</creator><creator>Amino, Itaru</creator><creator>Ochi, Ryutaro</creator><creator>Nakamura, Masakazu</creator><creator>Akimoto, Sachiko</creator><creator>Minami, Naoya</creator><creator>Fujiki, Naoto</creator><creator>Doi, Shizuki</creator><creator>Shimohama, Shun</creator><creator>Terayama, Yasuo</creator><creator>Kikuchi, Seiji</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope></search><sort><creationdate>20160915</creationdate><title>Fingolimod suppresses bone resorption in female patients with multiple sclerosis</title><author>Miyazaki, Yusei ; Niino, Masaaki ; Kanazawa, Ippei ; Suzuki, Masako ; Mizuno, Masanori ; Hisahara, Shin ; Fukazawa, Toshiyuki ; Takahashi, Eri ; Amino, Itaru ; Ochi, Ryutaro ; Nakamura, Masakazu ; Akimoto, Sachiko ; Minami, Naoya ; Fujiki, Naoto ; Doi, Shizuki ; Shimohama, Shun ; Terayama, Yasuo ; Kikuchi, Seiji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-7ca27b820a26924b4261052306efaf84fb91082c5cfc0542c9f08340e3d4f0f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Bone resorption</topic><topic>Bone Resorption - drug therapy</topic><topic>Bone Resorption - etiology</topic><topic>Collagen Type I - urine</topic><topic>Disability Evaluation</topic><topic>Female</topic><topic>Fingolimod</topic><topic>Fingolimod Hydrochloride - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - complications</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - urine</topic><topic>Neurology</topic><topic>Osteoclasts</topic><topic>Osteoporosis</topic><topic>Peptide Fragments - metabolism</topic><topic>Peptides - urine</topic><topic>Procollagen - metabolism</topic><topic>Sex Characteristics</topic><topic>Sphingosine-1-phosphate</topic><topic>Tartrate-Resistant Acid Phosphatase - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyazaki, Yusei</creatorcontrib><creatorcontrib>Niino, Masaaki</creatorcontrib><creatorcontrib>Kanazawa, Ippei</creatorcontrib><creatorcontrib>Suzuki, Masako</creatorcontrib><creatorcontrib>Mizuno, Masanori</creatorcontrib><creatorcontrib>Hisahara, Shin</creatorcontrib><creatorcontrib>Fukazawa, Toshiyuki</creatorcontrib><creatorcontrib>Takahashi, Eri</creatorcontrib><creatorcontrib>Amino, Itaru</creatorcontrib><creatorcontrib>Ochi, Ryutaro</creatorcontrib><creatorcontrib>Nakamura, Masakazu</creatorcontrib><creatorcontrib>Akimoto, Sachiko</creatorcontrib><creatorcontrib>Minami, Naoya</creatorcontrib><creatorcontrib>Fujiki, Naoto</creatorcontrib><creatorcontrib>Doi, Shizuki</creatorcontrib><creatorcontrib>Shimohama, Shun</creatorcontrib><creatorcontrib>Terayama, Yasuo</creatorcontrib><creatorcontrib>Kikuchi, Seiji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyazaki, Yusei</au><au>Niino, Masaaki</au><au>Kanazawa, Ippei</au><au>Suzuki, Masako</au><au>Mizuno, Masanori</au><au>Hisahara, Shin</au><au>Fukazawa, Toshiyuki</au><au>Takahashi, Eri</au><au>Amino, Itaru</au><au>Ochi, Ryutaro</au><au>Nakamura, Masakazu</au><au>Akimoto, Sachiko</au><au>Minami, Naoya</au><au>Fujiki, Naoto</au><au>Doi, Shizuki</au><au>Shimohama, Shun</au><au>Terayama, Yasuo</au><au>Kikuchi, Seiji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fingolimod suppresses bone resorption in female patients with multiple sclerosis</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2016-09-15</date><risdate>2016</risdate><volume>298</volume><spage>24</spage><epage>31</epage><pages>24-31</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Abstract Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N -telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27609272</pmid><doi>10.1016/j.jneuroim.2016.06.007</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 2016-09, Vol.298, p.24-31 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827915452 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Allergy and Immunology Bone resorption Bone Resorption - drug therapy Bone Resorption - etiology Collagen Type I - urine Disability Evaluation Female Fingolimod Fingolimod Hydrochloride - therapeutic use Humans Immunosuppressive Agents - therapeutic use Male Middle Aged Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Multiple Sclerosis - urine Neurology Osteoclasts Osteoporosis Peptide Fragments - metabolism Peptides - urine Procollagen - metabolism Sex Characteristics Sphingosine-1-phosphate Tartrate-Resistant Acid Phosphatase - metabolism |
| title | Fingolimod suppresses bone resorption in female patients with multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A47%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fingolimod%20suppresses%20bone%20resorption%20in%20female%20patients%20with%20multiple%20sclerosis&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Miyazaki,%20Yusei&rft.date=2016-09-15&rft.volume=298&rft.spage=24&rft.epage=31&rft.pages=24-31&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2016.06.007&rft_dat=%3Cproquest_cross%3E1818338020%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1818338020&rft_id=info:pmid/27609272&rft_els_id=S0165572816301394&rfr_iscdi=true |